메뉴 건너뛰기




Volumn 877, Issue 20-21, 2009, Pages 1894-1900

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum

Author keywords

AMN 107; Chronic myeloid leukemia; LC MS; Mass spectrometry; Nilotinib

Indexed keywords

AMN-107; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID LEUKEMIA; ELECTROSPRAY; HUMAN PLASMAS; INTER-ASSAY PRECISION; INTRA-ASSAY PRECISION; IONIZATION MASS SPECTROMETRY; LC-MS; NILOTINIB; ORAL ADMINISTRATION; PLASMA CONCENTRATION; PROTEIN PRECIPITATION; SMALL-MOLECULE INHIBITORS; TYROSINE KINASE INHIBITOR;

EID: 67049172866     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.05.034     Document Type: Article
Times cited : (29)

References (14)
  • 11
    • 67049091070 scopus 로고    scopus 로고
    • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM), Guidance for Industry-Bioanalytical Method Validation, http://www.fda.gov/cder/guidance/4252fnl.pdf, 2001.
    • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM), Guidance for Industry-Bioanalytical Method Validation, http://www.fda.gov/cder/guidance/4252fnl.pdf, 2001.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.